论文部分内容阅读
目的:探讨匹多莫德联合利巴韦林治疗小儿手足口病的效果。方法:治疗组采用匹多莫德联合利巴韦林治疗小儿手足口病80例,并以利巴韦林治疗的小儿手足口病78例作为对照组,疗程均为7天,观察其疗效。结果:临床症状及体征消退时间治疗组优于对照组(P<0.05);临床治疗组总有效率100.0%,对照组总有效率83.3%,两组比较差异有统计学意义(P<0.01),两组病例均未见明显的药物不良反应和严重并发证。结论:匹多莫德联合利巴韦林治疗小儿手足口病疗效高,无明显不良反应,未见严重并发证,值得临床推广应用。
Objective: To investigate the effect of pidotimod and ribavirin in the treatment of hand-foot-mouth disease in children. Methods: The treatment group used Pidotimod combined with ribavirin 80 cases of children with hand-foot-mouth disease and ribavirin in children treated 78 cases of hand-foot-mouth disease as a control group, the course of treatment were 7 days to observe its efficacy. Results: The clinical symptoms and signs of subsided time in the treatment group were better than those in the control group (P <0.05). The total effective rate was 100.0% in the clinical treatment group and 83.3% in the control group, with significant difference between the two groups (P <0.01) There was no obvious adverse drug reaction and severe concurrent syndrome in both groups. Conclusion: Pidotimod combined with ribavirin has a high therapeutic effect on HFMD in children with no obvious side effects and no serious complicated syndromes, which is worthy of clinical application.